John Colwell to Humans
This is a "connection" page, showing publications John Colwell has written about Humans.
Connection Strength
0.342
-
Does aspirin use reduce cardiovascular risk in diabetes? Nat Rev Endocrinol. 2009 Apr; 5(4):188-90.
Score: 0.012
-
Racial disparities in trends for cardiovascular disease and procedures among hospitalized diabetic patients. Ethn Dis. 2008; 18(2):131-5.
Score: 0.011
-
Diabetes-related lower extremity amputation rates fall significantly in South Carolina. South Med J. 2007 Aug; 100(8):787-90.
Score: 0.011
-
An appraisal of aspirin therapy in diabetes. Curr Diab Rep. 2006 Dec; 6(6):409-10.
Score: 0.010
-
Aspirin for the primary prevention of cardiovascular events. Drugs Today (Barc). 2006 Jul; 42(7):467-79.
Score: 0.010
-
Is aspirin effective in diabetic patients? Yes. J Thromb Haemost. 2005 Dec; 3(12):2612-4.
Score: 0.010
-
Aspirin therapy in diabetes. Diabetes Care. 2004 Jan; 27 Suppl 1:S72-3.
Score: 0.009
-
Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs. 2004; 4(2):87-106.
Score: 0.009
-
Aspirin for primary prevention of cardiovascular events in diabetes. Diabetes Care. 2003 Dec; 26(12):3349-50.
Score: 0.009
-
The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003 Jul; 26(7):2181-8.
Score: 0.008
-
Aspirin therapy in diabetes. Diabetes Care. 2003 Jan; 26 Suppl 1:S87-8.
Score: 0.008
-
Hemoglobin A1c is not the only issue. Curr Diab Rep. 2002 Aug; 2(4):295-6.
Score: 0.008
-
Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am. 2001 Dec; 30(4):1011-30.
Score: 0.007
-
New legislation covers reimbursement and diabetes care guidelines. J S C Med Assoc. 2000 Sep; 96(9):382-5.
Score: 0.007
-
Aspirin and risk of hemorrhagic stroke. JAMA. 1999 Aug 25; 282(8):731-2; author reply 732-3.
Score: 0.006
-
Overview of the Diabetes Initiative of South Carolina. J S C Med Assoc. 1998 Nov; 94(11):468-72.
Score: 0.006
-
Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care. 1998 Apr; 21(4):510-5.
Score: 0.006
-
Prevention of diabetes complications. Clin Cornerstone. 1998; 1(3):58-71.
Score: 0.006
-
Elevated plasma homocysteine and diabetic vascular disease. Diabetes Care. 1997 Dec; 20(12):1805-6.
Score: 0.006
-
Preventive care among people with diabetes in biracial population. J S C Med Assoc. 1997 Dec; 93(12):443-7.
Score: 0.006
-
Multifactorial aspects of the treatment of the type II diabetic patient. Metabolism. 1997 Dec; 46(12 Suppl 1):1-4.
Score: 0.006
-
Controlling type 2 diabetes: are the benefits worth the costs? JAMA. 1997 Nov 26; 278(20):1700.
Score: 0.006
-
Aspirin therapy in diabetes. Diabetes Care. 1997 Nov; 20(11):1767-71.
Score: 0.006
-
Pharmacological strategies to prevent macrovascular disease in NIDDM. Diabetes. 1997 Sep; 46 Suppl 2:S131-4.
Score: 0.006
-
Aspirin therapy in diabetes mellitus. Diabetologia. 1997 Jul; 40(7):867.
Score: 0.005
-
Should we use intensive insulin therapy after oral agent failure in type II diabetes? Diabetes Care. 1996 Aug; 19(8):896-8.
Score: 0.005
-
Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Diabetes. 1996 Jul; 45 Suppl 3:S87-90.
Score: 0.005
-
The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med. 1996 Jan 01; 124(1 Pt 2):131-5.
Score: 0.005
-
Forum Two: Unanswered research questions about metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996 Jan 01; 124(1 Pt 2):178-9.
Score: 0.005
-
Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care. 1995 Aug; 18(8):1150-5.
Score: 0.005
-
Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994 Aug; 17(8):818-23.
Score: 0.004
-
Is it time to introduce metformin in the U.S.? Diabetes Care. 1993 Apr; 16(4):653-5.
Score: 0.004
-
Vascular thrombosis in type II diabetes mellitus. Diabetes. 1993 Jan; 42(1):8-11.
Score: 0.004
-
Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators. Diabetes Care. 1993 Jan; 16(1):37-44.
Score: 0.004
-
Antiplatelet drugs and prevention of macrovascular disease in diabetes mellitus. Metabolism. 1992 May; 41(5 Suppl 1):7-10.
Score: 0.004
-
Clinical trials of antiplatelet agents in diabetes mellitus: rationale and results. Semin Thromb Hemost. 1991 Oct; 17(4):439-44.
Score: 0.004
-
Oral treatment of diabetes mellitus: the contribution of gliclazide. Am J Med. 1991 Jun 24; 90(6A):1S-2S.
Score: 0.004
-
Pathophysiology of vascular disease in diabetes: effects of gliclazide. Am J Med. 1991 Jun 24; 90(6A):50S-54S.
Score: 0.004
-
Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010 Jun 22; 55(25):2878-86.
Score: 0.003
-
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010 Jun; 33(6):1395-402.
Score: 0.003
-
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010 Jun 22; 121(24):2694-701.
Score: 0.003
-
Hemostatic alterations with exercise conditioning in NIDDM. Diabetes Care. 1990 Feb; 13(2):87-92.
Score: 0.003
-
V.A. Cooperative Study of antiplatelet agents in diabetic patients after amputation for gangrene: unobserved, sudden, and unexpected deaths. J Diabet Complications. 1989 Oct-Dec; 3(4):191-7.
Score: 0.003
-
A review of the development of large-vessel disease in diabetes mellitus. Am J Med. 1988 Nov 28; 85(5A):113-8.
Score: 0.003
-
President's address. Diabetes. 1988 Nov; 37(11):1449-52.
Score: 0.003
-
Antiplatelet agents and diabetic vascular disease. Trans Am Clin Climatol Assoc. 1987; 98:119-27.
Score: 0.003
-
Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med. 2006 Sep-Oct; 4(5):427-32.
Score: 0.003
-
Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care. 1986 Mar-Apr; 9(2):140-8.
Score: 0.002
-
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis. Haemostasis. 1986; 16(6):433-8.
Score: 0.002
-
Diabetic lipoprotein deficient serum: its effect in low density lipoprotein (LDL) uptake and degradation by fibroblasts. Metabolism. 1985 Dec; 34(12):1079-85.
Score: 0.002
-
Insulin and arachidonic acid metabolism in diabetes mellitus. Metabolism. 1985 Dec; 34(12 Suppl 1):32-6.
Score: 0.002
-
Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985 Nov; 34(11):1127-33.
Score: 0.002
-
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics. Horm Metab Res Suppl. 1985; 15:69-73.
Score: 0.002
-
Urinary kallikrein excretion in insulin-dependent diabetes mellitus and its relationship to glycemic control. J Clin Endocrinol Metab. 1984 Aug; 59(2):278-86.
Score: 0.002
-
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods, and baseline characteristics. Control Clin Trials. 1984 Jun; 5(2):165-83.
Score: 0.002
-
New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med. 1983 Nov 30; 75(5B):67-80.
Score: 0.002
-
Do platelets have anything to do with diabetic microvascular disease? Diabetes. 1983 May; 32 Suppl 2:14-9.
Score: 0.002
-
Effect of metabolic control on lipid, lipoprotein, and apolipoprotein levels in 55 insulin-dependent diabetic patients. A longitudinal study. Diabetes. 1983 Jan; 32(1):20-5.
Score: 0.002
-
Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982 Jun; 22(6):430-6.
Score: 0.002
-
Increased platelet arachidonic acid metabolism in diabetes mellitus. Diabetes. 1981; 30(Suppl 2):44-8.
Score: 0.002
-
Atherosclerosis in diabetes mellitus. J Chronic Dis. 1981; 34(1):1-4.
Score: 0.002
-
Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care. 1981 Jan-Feb; 4(1):121-33.
Score: 0.002
-
Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000 Oct; 23(10):1478-85.
Score: 0.002
-
Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care. 2000 Sep; 23(9):1316-20.
Score: 0.002
-
Platelet function in diabetes mellitus. Br J Haematol. 1980 Apr; 44(4):521-6.
Score: 0.002
-
The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications. 1999 Sep-Dec; 13(5-6):307-13.
Score: 0.002
-
Platelet adhesion and aggregation in diabetes mellitus. Metabolism. 1979 Apr; 28(4 Suppl 1):394-400.
Score: 0.002
-
Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med. 1998 Dec 7-21; 158(22):2485-90.
Score: 0.002
-
Diabetes research in South Carolina: past, present, and future. J S C Med Assoc. 1998 Nov; 94(11):502-8.
Score: 0.001
-
Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care. 1998 Apr; 21(4):574-9.
Score: 0.001
-
A critical issue. Intensive insulin treatment and macrovascular disease. Diabetes Care. 1998 Apr; 21(4):669-71.
Score: 0.001
-
Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease. Metabolism. 1977 Mar; 26(3):279-85.
Score: 0.001
-
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med. 1997 Jan 27; 157(2):181-8.
Score: 0.001
-
Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care. 1996 Dec; 19(12):1375-81.
Score: 0.001
-
Altered platelet function in diabetes mellitus. Diabetes. 1976; 25(2 SUPPL):826-31.
Score: 0.001
-
Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995 Aug; 18(8):1113-23.
Score: 0.001
-
Inhibition of labile aggregation-stimulating substance (LASS) and platelet aggregation in diabetes mellitus. Diabetes. 1975 Jul; 24(7):684-7.
Score: 0.001
-
A new case of xanthinuria. Am J Med. 1972 Nov; 53(5):690-2.
Score: 0.001
-
Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM) Diabetes Care. 1992 Nov; 15(11):1560-71.
Score: 0.001
-
Effect of resection of adipose tissue on the diabetes and hyperinsulinism of benign symmetric lipomatosis. Diabetes. 1972 Jan; 21(1):13-5.
Score: 0.001
-
Studies of insulin and growth hormone secretion in a subject with hepatoma and gypoglycemia. Diabetes. 1971 Sep; 20(9):607-14.
Score: 0.001
-
Pheochromocytoma and insulin. Ann Intern Med. 1969 Sep; 71(3):668-9.
Score: 0.001
-
Inhibition of insulin secretion by catecholamines in pheochromocytoma. Ann Intern Med. 1969 Aug; 71(2):251-6.
Score: 0.001
-
Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes. 1988 Dec; 37(12):1652-7.
Score: 0.001
-
Insulin secretion by insuloma and normal pancreas slices. Studies in a patient with multiple endocrine adenomata. Diabetes. 1968 Feb; 17(2):83-9.
Score: 0.001
-
Diminished insulin response to hyperglycemia in prediabetes and diabetes. Diabetes. 1967 Aug; 16(8):560-5.
Score: 0.001
-
Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986 Oct; 29(10):685-9.
Score: 0.001
-
Effect of diabetic control on retinopathy. Diabetes. 1966 Jul; 15(7):497-9.
Score: 0.001
-
Predicting insulin requirements for a portable insulin pump using the Biostator. Evidence for reversible insulin resistance in poorly controlled type I diabetics. Diabetes. 1983 Oct; 32(10):908-14.
Score: 0.001
-
Elevated glucose concentrations increase factor VIIIR:Ag levels in human umbilical vein endothelial cells. Diabetes. 1983 Sep; 32(9):876-8.
Score: 0.001
-
Platelet aggregation and release of ATP after incubation with soluble immune complexes purified from the serum of diabetic patients. Diabetes. 1981 Jul; 30(7):575-9.
Score: 0.000
-
Effect of metabolic control with insulin on plasma von Willebrand factor activity (VIIIR:WF) in diabetes mellitus. Thromb Res. 1980 Jan 1-15; 17(1-2):261-6.
Score: 0.000
-
Remission in disseminated coccidiodomycosis produced by amphotericin B. Ann Intern Med. 1959 Apr; 50(4):1028-35.
Score: 0.000
-
The effect of oral glucose on von Willebrand factor activity in normal and diabetic subjects. Clin Endocrinol (Oxf). 1977 Jun; 6(6):437-42.
Score: 0.000
-
Increased platelet aggregation in early diabetus mellitus. Ann Intern Med. 1975 Jun; 82(6):733-8.
Score: 0.000
-
Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation. Diabetes. 1972 Feb; 21(2):108-13.
Score: 0.000
-
Early recognition and therapy of disseminated coccidioidomycosis. Am J Med. 1961 Nov; 31:676-91.
Score: 0.000